Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Angiotensin Receptor Antagonists"" wg kryterium: Temat


Tytuł :
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Autorzy :
Baral R; Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom.; Department of Cardiology, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Tsampasian V; Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom.
Debski M; Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom.
Moran B; National Health Service 111 COVID-19 Clinical Assessment Service, Bicester, United Kingdom.; Neasden Medical Centre, London, United Kingdom.; Healix International, Esher, United Kingdom.
Garg P; Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom.; Department of Cardiology, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Clark A; Department of Medical Statistics, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Vassiliou VS; Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom.; Department of Cardiology, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Pokaż więcej
Źródło :
JAMA network open [JAMA Netw Open] 2021 Mar 01; Vol. 4 (3), pp. e213594. Date of Electronic Publication: 2021 Mar 01.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Renin-Angiotensin System*
Severity of Illness Index*
Angiotensin Receptor Antagonists/*pharmacology
Angiotensin-Converting Enzyme Inhibitors/*pharmacology
Antihypertensive Agents/*pharmacology
COVID-19/*mortality
Hypertension/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/adverse effects ; Antihypertensive Agents/therapeutic use ; COVID-19/epidemiology ; Comorbidity ; Female ; Humans ; Hypertension/epidemiology ; Male ; Middle Aged ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Autorzy :
Lee J; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Jo SJ; Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.
Cho Y; Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Lee JH; Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Oh IY; Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Park JJ; Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Cho YS; Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Choi DJ; Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Pokaż więcej
Źródło :
The Korean journal of internal medicine [Korean J Intern Med] 2021 Mar; Vol. 36 (Suppl 1), pp. S123-S131. Date of Electronic Publication: 2021 Feb 10.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Antihypertensive Agents/*therapeutic use
COVID-19/*therapy
Hypertension/*drug therapy
Renin-Angiotensin System/*drug effects
Administrative Claims, Healthcare ; Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Antihypertensive Agents/adverse effects ; COVID-19/diagnosis ; COVID-19/mortality ; Databases, Factual ; Female ; Humans ; Hypertension/diagnosis ; Hypertension/mortality ; Hypertension/physiopathology ; Male ; Middle Aged ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy.
Autorzy :
Nardin M; Division of Cardiology, Azienda Ospedaliera-Universitaria 'Maggiore della Carità', Eastern Piedmont University, Novara, Italy; Department of Medicine, ASST 'Spedali Civili', University of Brescia, Brescia, Italy.
Verdoia M; Division of Cardiology, Azienda Ospedaliera-Universitaria 'Maggiore della Carità', Eastern Piedmont University, Novara, Italy; Division of Cardiology, 'Ospedale degli Infermi', Biella, Italy.
Gioscia R; Division of Cardiology, Azienda Ospedaliera-Universitaria 'Maggiore della Carità', Eastern Piedmont University, Novara, Italy.
Negro F; Division of Cardiology, Azienda Ospedaliera-Universitaria 'Maggiore della Carità', Eastern Piedmont University, Novara, Italy.
De Luca G; Division of Cardiology, Azienda Ospedaliera-Universitaria 'Maggiore della Carità', Eastern Piedmont University, Novara, Italy. Electronic address: .
Pokaż więcej
Źródło :
Nutrition, metabolism, and cardiovascular diseases : NMCD [Nutr Metab Cardiovasc Dis] 2021 Apr 09; Vol. 31 (4), pp. 1276-1285. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji :
Journal Article
MeSH Terms :
Dual Anti-Platelet Therapy*/adverse effects
Percutaneous Coronary Intervention*/adverse effects
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Blood Platelets/*drug effects
Coronary Artery Disease/*therapy
Homocysteine/*blood
Platelet Aggregation/*drug effects
Aged ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Biomarkers/blood ; Blood Platelets/metabolism ; Coronary Artery Disease/blood ; Coronary Artery Disease/diagnostic imaging ; Female ; Humans ; Male ; Middle Aged ; Time Factors ; Treatment Outcome ; Up-Regulation
Czasopismo naukowe
Tytuł :
Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
Autorzy :
Tozuka T; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Yanagitani N; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yoshida H; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Manabe R; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ogusu S; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tsugitomi R; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Sakamoto H; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Amino Y; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ariyasu R; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Uchibori K; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kitazono S; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Seike M; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Gemma A; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Nishio M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Apr; Vol. 41 (4), pp. 2093-2100.
Typ publikacji :
Journal Article
MeSH Terms :
Angiotensin Receptor Antagonists/*pharmacology
Angiotensin-Converting Enzyme Inhibitors/*pharmacology
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antihypertensive Agents/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; B7-H1 Antigen/immunology ; Carcinoma, Non-Small-Cell Lung/complications ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Drug Synergism ; Female ; Humans ; Hypertension/complications ; Hypertension/drug therapy ; Hypertension/epidemiology ; Japan/epidemiology ; Lung Neoplasms/complications ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Nivolumab/therapeutic use ; Renin-Angiotensin System/drug effects ; Retrospective Studies ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding.
Autorzy :
Cohen JB; Renal-Electrolyte and Hypertension Division, Department of Medicine.; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
D'Agostino McGowan L; Department of Mathematics and Statistics, Wake Forest University.
Jensen ET; Department of Epidemiology and Prevention, Division of Public Health Sciences.
Rigdon J; Department of Biostatistics and Data Science, Division of Public Health Sciences.
South AM; Department of Epidemiology and Prevention, Division of Public Health Sciences.; Section of Nephrology, Department of Pediatrics, Brenner Children's Hospital.; Department of Surgery-Hypertension & Vascular Research.; Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.
Pokaż więcej
Źródło :
Journal of hypertension [J Hypertens] 2021 Apr 01; Vol. 39 (4), pp. 795-805.
Typ publikacji :
Journal Article; Review
MeSH Terms :
COVID-19*
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Renin-Angiotensin System/*drug effects
Angiotensin Receptor Antagonists/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Humans ; Hypertension/drug therapy ; Observational Studies as Topic ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer.
Autorzy :
Khoshghamat N; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Jafari N; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Toloue-Pouya V; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Azami S; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mirnourbakhsh SH; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Khazaei M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ferns GA; Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, UK.
Rajabian M; Department of Biology, Faculty of Science, Payame Noor University Po Box 19395-3697 Tehran, IRAN.
Avan A; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Apr 01; Vol. 270, pp. 119118. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Angiotensin Receptor Antagonists/*pharmacology
Angiotensin-Converting Enzyme Inhibitors/*pharmacology
Pancreatic Neoplasms/*drug therapy
Angiotensin II Type 1 Receptor Blockers/pharmacology ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/pharmacology ; Cardiovascular Diseases/drug therapy ; Drug Therapy, Combination ; Humans ; Hypertension/drug therapy ; Renin-Angiotensin System/drug effects
Czasopismo naukowe
Tytuł :
Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
Autorzy :
Haroon S; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Subramanian A; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Cooper J; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Anand A; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Gokhale K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Byne N; Cegedim Health Data, Cegedim Rx, London, UK.
Dhalla S; The Health Improvement Network (THIN), London, UK.
Acosta-Mena D; Cegedim Health Data, Cegedim Rx, London, UK.
Taverner T; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Okoth K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Wang J; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Chandan JS; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Sainsbury C; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.; Department of Diabetes, Gartnavel General Hospital, NHS Greater Glasgow and Clyde, Glasglow, UK.
Zemedikun DT; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Thomas GN; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Parekh D; Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.; Department of Acute Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Marshall T; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Sapey E; Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.; Department of Acute Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK.; PIONEER, The Health Data Research UK Hub in Acute Care, Birmingham, UK.
Adderley NJ; Institute of Applied Health Research, University of Birmingham, Birmingham, UK. .
Nirantharakumar K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.; Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Midlands Health Data Research UK, Birmingham, UK.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2021 Mar 15; Vol. 21 (1), pp. 262. Date of Electronic Publication: 2021 Mar 15.
Typ publikacji :
Journal Article
MeSH Terms :
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Antihypertensive Agents/*therapeutic use
COVID-19/*complications
Calcium Channel Blockers/*therapeutic use
Hypertension/*complications
Hypertension/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Antihypertensive Agents/adverse effects ; COVID-19/mortality ; Calcium Channel Blockers/adverse effects ; Cohort Studies ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Mortality ; Propensity Score ; Proportional Hazards Models ; Renin-Angiotensin System ; United Kingdom ; Young Adult
Czasopismo naukowe
Tytuł :
A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Autorzy :
Grover A; Internal Medicine, University of California, Irvine, School of Medicine, Irvine, CA, USA.
Oberoi M; Internal Medicine, University of South Dakota, Sanford School of Medicine, Sioux Falls, SD, USA.
Pokaż więcej
Źródło :
European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2021 Mar 15; Vol. 7 (2), pp. 148-157.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
SARS-CoV-2*
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
COVID-19/*complications
Adult ; Aged ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; COVID-19/mortality ; Humans ; Middle Aged ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.
Autorzy :
Volpe M; Cardiology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
Patrono C; Pharmacology, Catholic University School of Medicine, Rome, Italy and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Pokaż więcej
Źródło :
European heart journal [Eur Heart J] 2021 Mar 14; Vol. 42 (11), pp. 1061-1062.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Angiotensin Receptor Antagonists*
COVID-19*
Angiotensin-Converting Enzyme Inhibitors ; Hospitalization ; Hospitals ; Humans ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Autorzy :
Semenzato L; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Botton J; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Drouin J; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Baricault B; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Vabre C; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Cuenot F; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Penso L; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Herlemont P; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Sbidian E; Epidemiology in Dermatology and Evaluation of Therapeutics Research Unit, University Paris-Est Créteil (E.S.).
Weill A; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Dray-Spira R; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products, Saint-Denis, France and the French National Health Insurance, Paris, France (L.S., J.B., B.B., C.V., J.D., F.C., L.P., P.H., E.S., A.W., R.D.-S., M.Z.).
Zureik M; University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-Infective Evasion and Pharmacoepidemiology, CESP, 78180, Montigny le Bretonneux, France (M.Z.).
Pokaż więcej
Źródło :
Hypertension (Dallas, Tex. : 1979) [Hypertension] 2021 Mar 03; Vol. 77 (3), pp. 833-842. Date of Electronic Publication: 2021 Jan 11.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Pandemics*
Angiotensin Receptor Antagonists/*adverse effects
Angiotensin-Converting Enzyme 2/*drug effects
Angiotensin-Converting Enzyme Inhibitors/*adverse effects
Antihypertensive Agents/*adverse effects
COVID-19/*epidemiology
Hypertension/*drug therapy
Receptors, Virus/*drug effects
SARS-CoV-2/*physiology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/therapeutic use ; COVID-19/etiology ; Calcium Channel Blockers/adverse effects ; Calcium Channel Blockers/therapeutic use ; Comorbidity ; Disease Susceptibility ; Drug Utilization ; Female ; Follow-Up Studies ; France/epidemiology ; Hospital Mortality ; Hospitalization/statistics & numerical data ; Humans ; Hypertension/epidemiology ; Intubation, Intratracheal/statistics & numerical data ; Male ; Middle Aged ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Autorzy :
Shukla AK; Molecular and Human Genetics Laboratory, Department of Zoology, University of Lucknow, Lucknow, Uttar Pradesh, India.
Banerjee M; Molecular and Human Genetics Laboratory, Department of Zoology, University of Lucknow, Lucknow, Uttar Pradesh, India. .
Pokaż więcej
Źródło :
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2021 Mar; Vol. 28 (2), pp. 129-139. Date of Electronic Publication: 2021 Feb 26.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme 2/*antagonists & inhibitors
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
Diabetes Mellitus, Type 2/*drug therapy
Renin-Angiotensin System/*drug effects
SARS-CoV-2/*drug effects
Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme 2/metabolism ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Animals ; Antihypertensive Agents/therapeutic use ; Antiviral Agents/adverse effects ; Blood Pressure/drug effects ; COVID-19/enzymology ; COVID-19/virology ; COVID-19 Vaccines/therapeutic use ; Diabetes Mellitus, Type 2/enzymology ; Diabetes Mellitus, Type 2/physiopathology ; Host-Pathogen Interactions ; Humans ; Hypertension/drug therapy ; Hypertension/enzymology ; Hypertension/physiopathology ; Patient Safety ; Risk Assessment ; Risk Factors ; SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; Treatment Outcome ; Virus Internalization/drug effects
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea.
Autorzy :
Seo J; Department of Internal Medicine, Armed Forces Goyang Hospital, Goyang, Korea.
Son M; Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Korea.
Pokaż więcej
Źródło :
The Korean journal of internal medicine [Korean J Intern Med] 2021 Mar; Vol. 36 (Suppl 1), pp. S114-S122. Date of Electronic Publication: 2021 Feb 25.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Antihypertensive Agents/*therapeutic use
COVID-19/*epidemiology
Heart Failure/*drug therapy
Hypertension/*drug therapy
Renin-Angiotensin System/*drug effects
Aged ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Antihypertensive Agents/adverse effects ; COVID-19/diagnosis ; Case-Control Studies ; Databases, Factual ; Female ; Heart Failure/diagnosis ; Heart Failure/epidemiology ; Humans ; Hypertension/diagnosis ; Hypertension/epidemiology ; Male ; Middle Aged ; Republic of Korea/epidemiology ; Risk Assessment ; Risk Factors ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective.
Autorzy :
Kim HS; Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Kang M; Department of Health Information and Management, Chungbuk National University College of Medicine, 1 Chungdae-ro, Seowon-gu, Cheongju, 28644, Republic of Korea.
Kang G; Department of Health Information and Management, Chungbuk National University College of Medicine, 1 Chungdae-ro, Seowon-gu, Cheongju, 28644, Republic of Korea. .; Chungbuk Regional Cardiovascular Center, Chungbuk National University Hospital, Cheongju, Republic of Korea. .
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2021 Feb 15; Vol. 21 (1), pp. 175. Date of Electronic Publication: 2021 Feb 15.
Typ publikacji :
Journal Article
MeSH Terms :
Angiotensin Receptor Antagonists/*adverse effects
Angiotensin-Converting Enzyme Inhibitors/*adverse effects
COVID-19/*pathology
Aged ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; COVID-19/complications ; COVID-19/epidemiology ; Diabetes Mellitus/pathology ; Female ; Humans ; Hypertension/complications ; Hypertension/pathology ; Male ; Medical History Taking ; Middle Aged ; Pandemics ; Renin-Angiotensin System/drug effects ; Republic of Korea/epidemiology ; Retrospective Studies ; Risk Factors ; SARS-CoV-2/physiology
Czasopismo naukowe
Tytuł :
Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment.
Autorzy :
Lahens A; Physiology Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.
Mullaert J; INSERM, IAME, UMR 1137, Université de Paris.; Biostatistics, Epidemiology and Clinical Research Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.
Gressens S; Infectious and Tropical Diseases Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.
Gault N; Biostatistics, Epidemiology and Clinical Research Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.
Flamant M; Physiology Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.; Inserm U1149, Centre for Research on Inflammation, Université de Paris, Paris, France.
Deconinck L; Infectious and Tropical Diseases Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.
Joly V; Infectious and Tropical Diseases Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.
Yazdanpanah Y; INSERM, IAME, UMR 1137, Université de Paris.; Infectious and Tropical Diseases Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.
Lescure FX; INSERM, IAME, UMR 1137, Université de Paris.; Infectious and Tropical Diseases Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.
Vidal-Petiot E; Physiology Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital.; Inserm U1149, Centre for Research on Inflammation, Université de Paris, Paris, France.
Pokaż więcej
Źródło :
Journal of hypertension [J Hypertens] 2021 Feb 01; Vol. 39 (2), pp. 367-375.
Typ publikacji :
Journal Article
MeSH Terms :
Angiotensin Receptor Antagonists/*administration & dosage
Angiotensin-Converting Enzyme Inhibitors/*administration & dosage
COVID-19/*drug therapy
Aged ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; COVID-19/mortality ; Comorbidity ; Female ; Hospitalization ; Humans ; Logistic Models ; Male ; Middle Aged ; Odds Ratio ; Paris ; Patient Acuity ; Retrospective Studies ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension.
Autorzy :
Mancusi C; Department of Advanced Biomedical Sciences, Federico II University, Naples.
Grassi G; Department of Medicine and Surgery, University of Milan-Bicocca.
Borghi C; Department of Medicine and Surgery Sciences, Alma Mater Studiorum University of Bologna.
Carugo S; Health Sciences Department, University of Milan.
Fallo F; Clinica Medica 3, Department of Medicine, University of Padova.
Ferri C; Department of Clinical Medicine, Public Health, Life and Environment Sciences, University of L'Aquila.
Giannattasio C; Department of Medicine and Surgery, University of Milan-Bicocca.; Cardiology 4, 'A. De Gasperis' Department, ASST GOM Niguarda Ca' Granda Hospital, Milan.
Grassi D; Department of Clinical Medicine, Public Health, Life and Environment Sciences, University of L'Aquila.
Letizia C; Department of Translational and Precision Medicine, Unit of Secondary Arterial Hypertension, 'Sapienza' University of Rome, Policlinico 'Umberto I', Rome.
Minuz P; Department of Medicine, Section of Internal Medicine C, University of Verona.
Muiesan ML; Department of Clinical & Experimental Sciences, University of Brescia.; Medicina 2, ASST Spedali Civili Brescia.
Perlini S; Department of Emergency, IRCCS Policlinico San Matteo Foundation, Pavia.; Department of Internal Medicine and Therapeutics, University of Pavia.
Pucci G; Unit of Internal Medicine, AOU Santa Maria - Department of Medicine, University of Perugia, Terni.
Rizzoni D; Department of Clinical & Experimental Sciences, University of Brescia.
Salvetti M; Department of Clinical & Experimental Sciences, University of Brescia.
Sarzani R; Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, University 'Politecnica Delle Marche', Ancona.; Italian National Research Centre on Aging, Hospital 'U. Sestilli', IRCCS-INRCA, Ancona.
Sechi L; Department of Medicine, University of Udine.
Veglio F; Division of Internal Medicine and Hypertension, Department of Medical Sciences, AOU Città Salute e Scienza Torino, University of Torino.
Volpe M; Clinical and Molecular Medicine Department, Sapienza University Sant'Andrea Hospital, Rome.; IRCCS Neuromed, Pozzilli (IS), Italy.
Iaccarino G; Department of Advanced Biomedical Sciences, Federico II University, Naples.
Pokaż więcej
Corporate Authors :
SARS-RAS Investigators
Źródło :
Journal of hypertension [J Hypertens] 2021 Feb 01; Vol. 39 (2), pp. 376-380.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
COVID-19/*complications
Heart Failure/*complications
Renal Insufficiency, Chronic/*complications
Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Analysis of Variance ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Antihypertensive Agents/therapeutic use ; Chronic Disease ; Comorbidity ; Cross-Sectional Studies ; Female ; Heart Failure/epidemiology ; Hospitalization ; Humans ; Hypertension/epidemiology ; Italy/epidemiology ; Male ; Middle Aged ; Renal Insufficiency, Chronic/epidemiology ; Renin-Angiotensin System/drug effects ; SARS-CoV-2 ; Surveys and Questionnaires ; Young Adult
Czasopismo naukowe
Tytuł :
Evaluation of Drug Dissolution Rate in Co-amorphous and Co-crystal Binary Drug Delivery Systems by Thermodynamic and Kinetic Methods.
Autorzy :
Hu C; Medical College, Qinghai University, Xining, 810001, Qinghai, People's Republic of China. .; State Key Laboratory of Plateau Ecology and Agriculture, Qinghai University, Xining, 810001, Qinghai, People's Republic of China. .
Zhang F; Medical College, Qinghai University, Xining, 810001, Qinghai, People's Republic of China.
Fan H; Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Qinghai University, Xining, 810001, Qinghai, People's Republic of China.
Pokaż więcej
Źródło :
AAPS PharmSciTech [AAPS PharmSciTech] 2021 Jan 03; Vol. 22 (1), pp. 21. Date of Electronic Publication: 2021 Jan 03.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Delivery Systems*
Thermodynamics*
Aminobutyrates/*administration & dosage
Angiotensin Receptor Antagonists/*administration & dosage
Antihypertensive Agents/*administration & dosage
Tetrazoles/*administration & dosage
Valsartan/*administration & dosage
Aminobutyrates/chemistry ; Aminobutyrates/pharmacokinetics ; Angiotensin Receptor Antagonists/chemistry ; Angiotensin Receptor Antagonists/pharmacokinetics ; Animals ; Antihypertensive Agents/chemistry ; Antihypertensive Agents/pharmacokinetics ; Biological Availability ; Dogs ; Drug Combinations ; Drug Stability ; Kinetics ; Pharmaceutical Preparations ; Powder Diffraction ; Solubility ; Tetrazoles/chemistry ; Tetrazoles/pharmacokinetics ; Valsartan/chemistry ; Valsartan/pharmacokinetics
Czasopismo naukowe
Tytuł :
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox.
Autorzy :
Javanmard SH; Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Heshmat-Ghahdarijani K; Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Vaseghi G; Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Pokaż więcej
Źródło :
Infection control and hospital epidemiology [Infect Control Hosp Epidemiol] 2021 Jan; Vol. 42 (1), pp. 118-119. Date of Electronic Publication: 2020 May 04.
Typ publikacji :
Letter
MeSH Terms :
Angiotensin Receptor Antagonists*/pharmacology
Angiotensin Receptor Antagonists*/therapeutic use
COVID-19*/prevention & control
COVID-19*/therapy
COVID-19*/virology
SARS-CoV-2/*physiology
Angiotensin-Converting Enzyme 2/metabolism ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/metabolism ; Humans ; Medication Therapy Management ; Spike Glycoprotein, Coronavirus/metabolism ; Virus Internalization/drug effects
Opinia redakcyjna
Tytuł :
Metagenomic insights into dissemination of antibiotic resistance across bacterial genera in wastewater treatment.
Autorzy :
Cheng X; Civil Engineering Department, New Mexico State University, Las Cruces, NM, 88003, USA.
Xu J; Biology Department, New Mexico State University, Las Cruces, NM, 88003, USA.
Smith G; Biology Department, New Mexico State University, Las Cruces, NM, 88003, USA.
Zhang Y; Civil Engineering Department, New Mexico State University, Las Cruces, NM, 88003, USA. Electronic address: .
Pokaż więcej
Źródło :
Chemosphere [Chemosphere] 2021 May; Vol. 271, pp. 129563. Date of Electronic Publication: 2021 Jan 07.
Typ publikacji :
Journal Article
MeSH Terms :
Angiotensin Receptor Antagonists*
Water Purification*
Angiotensin-Converting Enzyme Inhibitors ; Anti-Bacterial Agents/pharmacology ; Bacteria/genetics ; Drug Resistance, Bacterial/genetics ; Drug Resistance, Microbial/genetics ; Genes, Bacterial ; Waste Water
Czasopismo naukowe
Tytuł :
Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19.
Autorzy :
Soleimani A; Department of Cardiology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Kazemian S; Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.
Karbalai Saleh S; Department of Cardiology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Aminorroaya A; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.; Department of cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Shajari Z; Department of Cardiology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Hadadi A; Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Talebpour M; Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sadeghian H; Department of Cardiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Payandemehr P; Department of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sotoodehnia M; Department of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Bahreini M; Department of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Najmeddin F; Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Heidarzadeh A; Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.
Zivari E; Research Development Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ashraf H; Research Development Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.; Cardiac Primary Prevention Research Center (CPPRC), Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
American journal of hypertension [Am J Hypertens] 2020 Dec 31; Vol. 33 (12), pp. 1102-1111.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiotensin Receptor Antagonists/*therapeutic use
Antihypertensive Agents/*therapeutic use
COVID-19/*therapy
Hypertension/*drug therapy
Acute Kidney Injury/mortality ; Aged ; Angiotensin Receptor Antagonists/adverse effects ; Antihypertensive Agents/adverse effects ; COVID-19/diagnosis ; COVID-19/mortality ; Female ; Hospital Mortality ; Hospitalization ; Humans ; Hypertension/diagnosis ; Hypertension/mortality ; Iran ; Male ; Middle Aged ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies